Overview
Vilon (Lys-Glu / KE) is a synthetic ultra-short dipeptide bioregulator designed to stimulate the thymus gland and activate immune tissue regeneration.
What problem it targets: It targets post-surgical immune depression, chronic wound non-healing, age-related thymus involution, and suppressed cellular immunity.
What It Does
• Reactivates thymus and immune signaling: Rapidly stimulates the proliferation of thymic epithelial cells, revitalizing natural T-cell maturation and immune defenses.
• Accelerates physical wound healing: Promotes fibroblast proliferation and accelerates granulation tissue formation in surgical wounds and skin lesions.
• Modulates chromatin in aging immune cells: Decondenses heterochromatin in aged lymphocytes, restoring youthful gene expression and cellular defense capabilities.
• Realistic expectations: Administered in short 10- to 20-day cycles. Acts as a potent cellular immune rejuvenation peptide, enhancing physical recovery and infection resistance.
Reconstitution
| Vial Size | BAC Water / Solvent | Concentration |
|---|---|---|
| 20 mg (assumed vial strength) | 2 mL bacteriostatic water (requested mixing example) | 10 mg/mL = 10,000 micrograms/mL |
Reconstitution Calculator
Enter the vial amount and diluent volume to calculate concentration. If you already have a target amount, you can also convert it to liquid volume and syringe markings. This tool does not recommend a target amount.
Enter a target amount you already have and select the syringe capacity.
Mathematical reference only. The calculator does not determine an appropriate target amount. Syringe capacity only changes the maximum volume that fits.
Presentation
20 mg vial used for the mixing example. Other sizes exist. Confirm the actual peptide content and sequence on the batch documentation.
Protocol
Community protocols & cycle timing
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Common community cycle pattern | 10–20 consecutive days; a few courses per year with months between courses | Compound- and formulation-specific; see rows below | A shared cycle duration does not establish one shared dose. Oral labels may specify 30-day initial courses or 10-day maintenance courses. |
Research study amounts
| Phase | Frequency | Amount | Notes |
|---|---|---|---|
| Cultured human lymphocytes | Added after 24 hours; 72-hour culture endpoint | 0.01 microgram/mL | 2023 chromatin study; culture concentration, not an oral or injected human dose. |
About these protocols
The community rows describe reported experience, not a standard or recommended human regimen. Product-label rows apply to the cited formulation; cell and animal rows describe research models. The 20 mg / 2 mL table is a concentration example using the requested assumptions. Solvent compatibility and stability are product-specific.
Handling & Stacking
- Bioregulators are often discussed as short 10–20-day courses, repeated a few times a year with months between courses, rather than continuous daily use.
- This describes a community cycle pattern, not one universal dose.
- Some finished oral products instead specify a 30-day course or 10-day maintenance course.
- Where users report subcutaneous administration, the abdomen or outer thigh are common subcutaneous sites.
- This does not establish an approved administration route for this compound.
- No compound-specific universal storage temperature or post-mixing stability period was verified.
- Use the supplier’s stability data for that formulation.
- Keep identity, lot, preparation date and final concentration traceable; a purity percentage alone does not establish sterility or stability.
- The named preparation is not established here as an approved treatment for its marketed goals.
- Approved alternatives depend on the diagnosed condition and cannot be assigned from an organ label alone.
